Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega ...

X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Parse has now invalidated all claims that 10x Genomics asserts against Parse products, further reinforcing Parse’s ability to drive ongoing innovation in the single cell space. In defense of ...

This collaboration will use 10x Genomics' Chromium GEM-X technology for single-cell analysis. Launched in 2024, the GEM-X technology architecture delivers superior sensitivity, throughput ...

Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone formation in the spine, leading to severe neurological symptoms due to spinal ...

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG ... view on 10x’s positioning in the single cell and spatial markets, but remains on the sidelines ...